【Abstract】Objective To investigate the correlation between G-395A polymorphism in klotho gene and autogenous arteriovenous fistula (AVF) dysfunction in maintenance hemodialysis (MHD) patients. Methods This prospective study included 198 MHD patients undergoing AVF surgery at Jiangsu Province Subei People's Hospital in the period from January 2015 to January 2018. The singlEnucleotide polymorphism at the G-395A in Klotho gene was identified by first generation sequencing. Serum klotho and FGF23 levels were measured by ELISA. Clinical and biochemical data were collected. Cox regression model was used to analyze the relevant factors affecting the life span of AVF. Results These MHD patients were followed up for 2 years, in which 5 lost the follow-up, and 3 died. The survival rates of AVF after one and two years were 88.9% and 77.8%, respectively. According to the presence or absence of A allele, the patients were divided into A allele carriers (GA genotype or AA genotype) and non-A carriers (GG genotype). The patency rate was lower in A allele carriers than in non-A carriers (χ2=9.062, P=0.003). Multivariate Cox proportional hazards model showed that genotype (HR=2.664, 95% CI: 1.594-～4.452, P<0.001), history of catheterization (HR=2.299, 95% CI:1.048～5.045, P=0.038) and FGF23 level (HR=1.002, 95% CI: 1.000～1.003, P=0.009) were the factors influencing long-term patency of AVF. Conclusion The G-395A polymorphism in klotho gene may relate to the long-term patency of autogenous AVF in MHD patients, and A allele may be an independent risk factor for AVF failure.
[1] Masaki T, Yorioka N, Kyuden Y, et al. Factors influencing arteriovenous fistula dysfunction in Japanese patients on chronic hemodialysis[J]. Int J Artif Organs, 1999, 22(1): 14-17.
[2] Dember LM, Imrey PB, Beck GJ, et al. Objectives and design of the hemodialysis fistula maturation study[J]. American Journal of Kidney Diseases, 2014, 63(1): 104-112.
[3] Lee T, Wadehra D. Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction[J]. Semin Dial, 2012, 25(1): 65-73.
[4] 佟颜杉. CKD5期患者klotho基因多态性及其表达蛋白与钙磷代谢紊乱的相关性. In: 扬州大学, 2017.
[5] 徐艳. Klotho基因多态性与重度继发性甲状旁腺功能亢进相关性研究. In: 扬州大学, 2018.
[6] Viecelli AK, Mori TA, Roy-Chaudhury P, et al. The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled[J]. Semin Dial, 2018, 31(3): 244-257.
[7] 金其庄, 王玉柱, 叶朝阳, et al. 中国血液透析用血管通路专家共识(第2版)[J]. 中国血液净化, 2019, (06): 365-381.
[8] Yu L, Kang L, Ren XZ, et al. Circulating alpha-Klotho Levels in Hemodialysis Patients and Their Relationship to Atherosclerosis[J]. Kidney Blood Press Res, 2018, 43(4): 1174-1182.
[9] Al-Jaishi AA, Oliver MJ, Thomas SM, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis[J]. Am J Kidney Dis, 2014, 63(3): 464-478.
[10] 汪晶晶. 315例常州地区血液透析患者病因及高血压和贫血现况调查. In: 苏州大学, 2017.
[11] 袁红波, 楼季庄, 季大玺, et al. 2014年南京市多中心血液透析质量调查分析[J]. 中国中西医结合肾病杂志, 2015, (06): 544-545.
[12] Park KA, Jo HM, Han JS, et al. Features of atherosclerosis in hemodialysis patients[J]. Kidney Res Clin Pract, 2013, 32(4): 177-182.
[13] Kato A, Takita T, Maruyama Y, et al. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients[J]. Kidney international, 2003, 64(4): 1472-1479.
[14] Nicolosi AC, Pohl LL, Parsons P, et al. Increased incidence of radial artery calcification in patients with diabetes mellitus[J]. J Surg Res, 2002, 102(1): 1-5.
[15] Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control[J]. Journal of the American College of Cardiology, 2001, 38(5): 1307-1312.
[16] Lok CE, Allon M, Moist L, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I)[J]. Journal of the American Society of Nephrology, 2006, 17(11): 3204-3212.
[17] Arhuidese IJ, Orandi BJ, Nejim B, et al. Utilization, patency, and complications associated with vascular access for hemodialysis in the United States[J]. J Vasc Surg, 2018, 68(4): 1166-1174.
[18] John GB, Cheng C-Y, Kuro-o M. Role of Klotho in aging, phosphate metabolism, and CKD[J]. American Journal of Kidney Diseases, 2011, 58(1): 127-134.
[19] Saito Y, Nakamura T, Ohyama Y, et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome[J]. Biochemical and biophysical research communications, 2000, 276(2): 767-772.
[20] Takeshita K, Yamamoto K, Ito M, et al. Increased Expression of Plasminogen Activator Inhibitor-1 with Fibrin Deposition in a Murine Model of Aging. In: Seminars in thrombosis and hemostasis, Vol. 28: Copyright? 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New?…, 2002: 545-554.
[21] Zeng QY, Xia ZY, Tong YS, et al. Association of klotho gene polymorphism and the regulation of calcium-phosphate metabolism disorders in patients with end-stage renal disease[J]. Nephrology (Carlton), 2018.
[22] Kim Y, Jeong SJ, Lee HS, et al. Polymorphism in the promoter region of the klotho gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients[J]. Korean J Intern Med, 2008, 23(4): 201-207.
[23] Zohny SF, El-Fattah MA, Khan JA. Circulating Fibroblast Growth Factor-23 Level and Paraoxonase-1 Lactonase Activity in Chronic Hemodialysis Patients: Their Impact on the Incidence of Native AV Fistula Thrombosis[J]. Clinical and Investigative Medicine, 2016: E173-E181.
[24] Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community[J]. Atherosclerosis, 2009, 205(2): 385-390.
[25] Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease[J]. Kidney international, 2010, 78(10): 975-980.
[26] Kitagawa M, Sugiyama H, Morinaga H, et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease[J]. PLoS One, 2013, 8(2): e56695.
[27] Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study[J]. Nephrology Dialysis Transplantation, 2012, 28(2): 352-359.
[28] Yokoyama K, Imura A, Ohkido I, et al. Serum soluble α-klotho in hemodialysis patients[J]. Clinical nephrology, 2012, 77(5): 347-351.
[29] van Kimmenade RR, Mohammed AA, Uthamalingam S, et al. Red blood cell distribution width and 1‐year mortality in acute heart failure[J]. European journal of heart failure, 2010, 12(2): 129-136.
[30] Bojakowski K, Dzabic M, Kurzejamska E, et al. A high red blood cell distribution width predicts failure of arteriovenous fistula[J]. PLoS One, 2012, 7(5): e36482.
[31] Pisoni RL, Young EW, Dykstra DM, et al. Vascular access use in Europe and the United States: results from the DOPPS[J]. Kidney international, 2002, 61(1): 305-316.
